TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: GlobeNewswire
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference, being held at the Lotte New York Palace Hotel in New York City. The presentation is scheduled to take place on Wednesday, June 19, 2019 at 9:10 AM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/28/24 - Beat
TGTX
Sec Filings
- 4/18/24 - Form PRE
- 3/15/24 - Form 4
- 3/13/24 - Form 4
- TGTX's page on the SEC website